{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-035212","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.254036+00:00","generated_at":"2026-05-31T13:39:02.644716+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Galectin Therapeutics promotes Khurram Jamil to CMO, replacing Pol Boudes","bullets":["Dr. Jamil appointed Chief Medical Officer effective August 1, 2024, succeeding Dr. Pol Boudes.","Annual base salary of $500,000, 30% target bonus, 10,000 restricted shares, options for 100,000 shares.","Jamil joined Galectin in March 2024 as VP Clinical Development; previously at Mallinckrodt Pharmaceuticals.","Company reaffirms interim analysis of NAVIGATE Phase 2b/3 trial for belapectin in December 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-035212","json":"https://secwatch.observer/filing/0001140361-24-035212.json","markdown":"https://secwatch.observer/filing/0001140361-24-035212.md","text":"https://secwatch.observer/filing/0001140361-24-035212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/0001140361-24-035212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/ef20033332_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:39:02.644716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ced4f11026","claim":"Pol Boudes resigned as Chief Medical Officer at GALECTIN THERAPEUTICS INC.","evidence_excerpt":"Dr. Jamil succeeds Dr. Pol Boudes as Chief Medical Officer of the Company, who resigned on July 26, 2024. Dr. Boudes’s last day of employment with the Company is August 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/0001140361-24-035212-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"e0bf0b5f91","claim":"Khurram Jamil changed role as Chief Medical Officer at GALECTIN THERAPEUTICS INC.","evidence_excerpt":"On August 1, 2024, Galectin Therapeutics Inc. (the “Company”) announced the promotion of Dr. Khurram Jamil to Chief Medical Officer effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/0001140361-24-035212-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}